Display options
Cite
Huang B, Duan Y. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019;22(4):239-244doi: 10.3779/j.issn.1009-3419.2019.04.07.
Huang, B., & Duan, Y. (2019). [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 22(4), 239-244. https://doi.org/10.3779/j.issn.1009-3419.2019.04.07
Huang, Benlin, and Duan, Yong. "[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]." Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 22,4 (2019): 239-244. doi: https://doi.org/10.3779/j.issn.1009-3419.2019.04.07
Huang B, Duan Y. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07. Chinese. PMID: 31014443; PMCID: PMC6500500.
Copy Download .nbib Format: NLM
Share it on

Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07.

[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer

[Article in Chinese]
Benlin Huang, Yong Duan

Affiliations

  1. Department of Clinical Laboratory, the First Affiliated Hospital of Kunming Medical University; Yunnan Institute of Experimental Diagnosis; Yunnan Key Laboratory of Laboratory Medicine, Kunming 650032, China.

PMID: 31014443 PMCID: PMC6500500 DOI: 10.3779/j.issn.1009-3419.2019.04.07

Abstract

With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment strategy. The appearance of immune checkpoint inhibitors brings new hope for SCLC. Several clinical trials have demonstrated the persistent efficacy and clinical activity of the programmed death receptor/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the treatment of SCLC. However, its efficacy and safety are not very accurate, and the markers that can effectively predict the efficacy of immunotherapy have not been concluded. In this paper, for further changing the treatment strategy of SCLC clinical practice and providing theoretical basis of research, we reviewed the progress of immune checkpoint inhibitors, related markers in the treatment of SCLC by exploring the value, problems and challenges of immunotherapy in SCLC.
.

Keywords: CTLA-4; Immune checkpoint inhibitors; PD-1; PD-L1; Small cell lung cancer

References

  1. Lancet. 2018 Mar 10;391(10124):933 - PubMed
  2. Lancet Oncol. 2016 Jul;17(7):883-895 - PubMed
  3. J Clin Oncol. 2017 Dec 1;35(34):3823-3829 - PubMed
  4. Cell. 2015 Jan 15;160(1-2):48-61 - PubMed
  5. J Thorac Dis. 2018 Feb;10(Suppl 3):S460-S467 - PubMed
  6. N Engl J Med. 2016 Nov 03;375(18):1749-1755 - PubMed
  7. J Thorac Oncol. 2013 May;8(5):587-98 - PubMed
  8. Eur Respir J. 2010 Jan;35(1):202-15 - PubMed
  9. Transl Lung Cancer Res. 2016 Feb;5(1):26-38 - PubMed
  10. Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8 - PubMed
  11. N Engl J Med. 2017 Dec 21;377(25):2500-2501 - PubMed
  12. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 - PubMed
  13. Cancer. 2015 Mar 1;121(5):664-72 - PubMed
  14. J Clin Oncol. 2015 Jun 20;33(18):2004-12 - PubMed
  15. Nat Genet. 2012 Oct;44(10):1104-10 - PubMed
  16. Mol Cancer Ther. 2015 Apr;14(4):847-56 - PubMed
  17. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
  18. Ann Oncol. 2013 Jan;24(1):75-83 - PubMed
  19. J Clin Oncol. 1999 Feb;17(2):658-67 - PubMed
  20. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  21. J Clin Oncol. 2018 Apr 1;36(10):1020-1044 - PubMed
  22. J Clin Oncol. 2016 Nov 1;34(31):3740-3748 - PubMed
  23. Nat Immunol. 2007 Mar;8(3):239-45 - PubMed
  24. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  25. Future Oncol. 2016 Apr;12(7):931-43 - PubMed
  26. Cancer Cell. 2018 May 14;33(5):853-861.e4 - PubMed

MeSH terms

Publication Types